Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1

Status

Completed 34Terminated 4Unknown 3Active not recruiting 3Recruiting 2Withdrawn 1

Sponsor Class

NETWORK 1FED 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 2Neoplasm Metastasis 1

Interventions

Magnetic Resonance Spectroscopy 51Specimen Handling 42enzalutamide 35Androgen Antagonists 34Radiosurgery 32Radiotherapy 31Prednisone 26darolutamide 24Abiraterone Acetate 24Leuprolide 22Docetaxel 22apalutamide 20Pluvicto 19abiraterone 18Standard of Care 18Triptorelin Pamoate 17Radiation 17Biopsy 16relugolix 15acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 15Goserelin 14Blood Specimen Collection 13gallium 68 PSMA-11 12pembrolizumab 11X-Rays 11Surveys and Questionnaires 11luprolide acetate gel depot 10Carboplatin 10Methods 9Interviews as Topic 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Prostatic Neoplasms × Flutamide × Clear all
NCT04787744 2026-04-08

VA STARPORT

VA Office of Research and Development

Phase 2/3 Recruiting
464 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT03678025 2025-09-11

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

SWOG Cancer Research Network

Phase 3 Recruiting
1,273 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡